Equities Analysts Offer Predictions for APLS Q1 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at Wedbush cut their Q1 2025 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.43). Wedbush has a “Neutral” rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.59) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $3.50 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The company had revenue of $212.50 million during the quarter, compared to analysts’ expectations of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.73) earnings per share.

A number of other brokerages also recently weighed in on APLS. Royal Bank of Canada decreased their price target on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a report on Monday, March 3rd. The Goldman Sachs Group lowered their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Scotiabank raised their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. upped their price target on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.59.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $18.20 on Friday. Apellis Pharmaceuticals has a fifty-two week low of $17.49 and a fifty-two week high of $50.98. The stock has a market cap of $2.28 billion, a PE ratio of -8.97 and a beta of 0.85. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm’s fifty day moving average price is $23.93 and its two-hundred day moving average price is $28.07.

Insiders Place Their Bets

In related news, CEO Cedric Francois sold 13,551 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $412,356.93. Following the completion of the sale, the chief executive officer now owns 418,519 shares in the company, valued at $12,735,533.17. The trade was a 3.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company’s stock, valued at $3,482,123. This represents a 3.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,011 shares of company stock valued at $1,059,969 in the last ninety days. Insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its stake in Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock worth $390,011,000 after buying an additional 1,111,111 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Apellis Pharmaceuticals by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company’s stock valued at $320,569,000 after acquiring an additional 230,450 shares during the period. JPMorgan Chase & Co. raised its position in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares during the last quarter. Jennison Associates LLC boosted its stake in Apellis Pharmaceuticals by 51.6% during the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after purchasing an additional 939,289 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 127.2% during the 4th quarter. AQR Capital Management LLC now owns 1,856,442 shares of the company’s stock worth $59,239,000 after purchasing an additional 1,039,182 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).